Shun-Xin Li

Shun-Xin Li

Auto-generated profile, based on publicly available information

Shun-Xin Li

Department of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Gut and Liver
Verified
Journal Article
Open access
PDF file
YHYi-Fan Hu
Yi-Fan Hu
SLShun-Xin Li
Shun-Xin Li
HLHong-Li Liu
Hong-Li Liu
ZDZhixiang Du
Zhixiang Du
SWShuang-Shuang Wang
Shuang-Shuang Wang
YYYong-Feng Yang
Yong-Feng Yang
Yi-Fan Hu, Shun-Xin Li, Hong-Li Liu, Zhi-Xiang Du, Shuang-Shuang Wang, Miao-Yang Chen, Li Wang, Qing-Fang Xiong, Yan-Dan Zhong, Du-Xian Liu, Yong-Feng Yang. Gut and Liver 2024;18:867-76. https://doi.org/10.5009/gnl230468

26 September 2024 in Clinics
Verified
Journal Article
Open access
MCMiao-Yang Chen
Miao-Yang Chen
SLShun-Xin Li
Shun-Xin Li
ZDZhi-Xiang Du
Zhi-Xiang Du
QXQing-Fang Xiong
Qing-Fang Xiong
YZYan-Dan Zhong
Yan-Dan Zhong
YYYong-Feng Yang
Yong-Feng Yang
The role of Non-Alcoholic Fatty Liver Disease (NAFLD) on antiviral response in Chronic Hepatitis B (CHB) remains unclear. Previous studies mainly focus on the impact of the Non-Alcoholic Fatty Liver (NAFL) on antiviral efficacy, whereas the role of Non-Alcoholic Steatohepatitis (NASH) has not been highlighted. The authors aimed to investigate the association of NAFLD (NAFL and NASH), viral and histological characteristics with antiviral response. The authors collected data of treatment-naïve CHB patients who underwent liver biopsy. All these patients received antiviral monotherapy and 48-week follow-up. The antiviral response was evaluated by Kaplan-Meier analysis. Cox regression analysis identified the variables associated with antiviral response. Overall, 120 treatment-naïve CHB patients were enrolled, with 49.2 % (59/120) of them were complicated by NAFLD. Male (Odd Ratio [OR = 4.222], 95 % Confidence Interval [95 % CI 1.620-11.003]) and overweight (OR = 8.709, 95 % CI 3.355-22.606) were independent predictors for concurrent NAFLD. After 48-week follow-up, the authors found that the overall antiviral response did not differ between CHB patients with and without concomitant NAFL/NASH (p > 0.05). High viral load (Hazard Ratio [HR = 0.522], 95 % CI 0.286-0.952), advanced fibrosis (HR = 2.426, 95 % CI 1.256-4.686), and moderate-to-severe interface hepatitis (HR = 2.541, 95 % CI 1.406-4.592) were significantly correlated with antiviral response after 8-week follow-up. Neither NAFL nor NASH had an impact on antiviral therapy for CHB. It was low hepatitis B load, advanced fibrosis, and moderate-to-severe interface hepatitis that contributed to the virological response.